This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …

Cisplatin, oxaliplatin, paclitaxel, vincristine and bortezomib are some of the most effective
drugs successfully employed (alone or in combinations) as first-line treatment for common …

Abstract Paclitaxel (Brand name Taxol) is widely used in the treatment of common cancers
like breast, ovarian and lung cancer. Although highly effective in blocking tumor progression …

Peripheral neuropathy is a severe dose limiting toxicity associated with cancer
chemotherapy. Ever since it was identified, the clear pathological mechanisms underlying …

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

Chemotherapy-induced peripheral neuropathic pain (CIPNP)—a severe adverse effect
observed in up to 80% of patients during treatment with antineoplastic drugs—limits the …

Chemotherapy induced peripheral neuropathy (CIPN) is a type of neuropathic pain that is a
major dose-limiting side-effect of potentially curative cancer chemotherapy treatment …

Anti-cancer drugs such as vincristine, paclitaxel, oxaliplatin, cisplatin and bortezomib are
well reported to exert direct and indirect effects on sensory nerves to alter the amplitude of …

Paclitaxel is a microtubule-binding compound that is widely used as a chemotherapeutic in
the treatment of common cancers, including breast and ovarian cancer. Paclitaxel binding …